136 related articles for article (PubMed ID: 22849428)
1. Iloperidone, asenapine and lurasidone: a primer on their current status.
Tarazi FI; Stahl SM
Expert Opin Pharmacother; 2012 Sep; 13(13):1911-22. PubMed ID: 22849428
[TBL] [Abstract][Full Text] [Related]
2. Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic.
Citrome L
Clin Schizophr Relat Psychoses; 2011 Jan; 4(4):251-7. PubMed ID: 21177242
[TBL] [Abstract][Full Text] [Related]
3. Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy.
Miura I; Horikoshi S; Ichinose M; Suzuki Y; Watanabe K
Drug Des Devel Ther; 2023; 17():3023-3031. PubMed ID: 37789971
[TBL] [Abstract][Full Text] [Related]
4. Asenapine Transdermal Patch for the Management of Schizophrenia.
Zhou M; Derakhshanian S; Rath A; Bertrand S; DeGraw C; Barlow R; Menard A; Kaye AM; Hasoon J; Cornett EM; Kaye AD; Viswanath O; Urits I
Psychopharmacol Bull; 2020 Sep; 50(4):60-82. PubMed ID: 33012873
[TBL] [Abstract][Full Text] [Related]
5. Optimal dose for the efficacy of asenapine in patients with schizophrenia: Real-world data.
Takekita Y; Hiraoka S; Iwama Y; Matsui D; Aoki N; Ogata H; Funatsuki T; Shimizu T; Murase Y; Koshikawa Y; Kato M; Kinoshita T
Neuropsychopharmacol Rep; 2024 Mar; 44(1):234-239. PubMed ID: 37926930
[TBL] [Abstract][Full Text] [Related]
6. Cocaine-Induced Psychosis and Asenapine as Treatment: A Case Study.
Palma-Álvarez RF; Ros-Cucurull E; Ramos-Quiroga JA; Roncero C; Grau-López L
Psychopharmacol Bull; 2019 Feb; 49(1):92-97. PubMed ID: 30858643
[TBL] [Abstract][Full Text] [Related]
7. Effect of single-administration of D-sorbitol pretreatment on the bitterness and continued willingness to take asenapine: a randomized, single-blind, placebo-controlled, crossover trial.
Wada S; Iwamoto K; Okumura H; Hida H; Hiraoka S; Kamei A; Mori D; Yamada K; Ando M; Ozaki N; Ikeda M
BMC Psychiatry; 2024 Jan; 24(1):81. PubMed ID: 38291403
[TBL] [Abstract][Full Text] [Related]
8. FDA-Approved Drugs to Treat Schizophrenia.
J Psychosoc Nurs Ment Health Serv; 2023 Dec; 61(12):5-6. PubMed ID: 38051683
[No Abstract] [Full Text] [Related]
9. The Novel Antipsychotic Lumateperone (Iti-007) in the Treatment of Schizophrenia: A Systematic Review.
Longo G; Cicolini A; Orsolini L; Volpe U
Brain Sci; 2023 Nov; 13(12):. PubMed ID: 38137089
[TBL] [Abstract][Full Text] [Related]
10. Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults.
Bobo WV
Expert Rev Clin Pharmacol; 2013 Jan; 6(1):61-91. PubMed ID: 23272794
[TBL] [Abstract][Full Text] [Related]
11. Potential use of lurasidone for the treatment of bipolar psychosis.
Carta MG; Moro MF; Nardi AE; Calabrese JR
Expert Opin Investig Drugs; 2015 Apr; 24(4):575-84. PubMed ID: 25633339
[TBL] [Abstract][Full Text] [Related]
12. Management of bipolar I depression: clinical utility of lurasidone.
Findlay LJ; El-Mallakh P; El-Mallakh RS
Ther Clin Risk Manag; 2015; 11():75-81. PubMed ID: 25609973
[TBL] [Abstract][Full Text] [Related]
13. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach.
Citrome L
CNS Drugs; 2013 Nov; 27(11):879-911. PubMed ID: 24062193
[TBL] [Abstract][Full Text] [Related]
14. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
De Hert M; Yu W; Detraux J; Sweers K; van Winkel R; Correll CU
CNS Drugs; 2012 Sep; 26(9):733-59. PubMed ID: 22900950
[TBL] [Abstract][Full Text] [Related]
15. Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics.
Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Pae CU
Clin Neuropharmacol; 2013; 36(6):223-38. PubMed ID: 24201235
[TBL] [Abstract][Full Text] [Related]
16. Newer antipsychotics and upcoming molecules for schizophrenia.
George M; Amrutheshwar R; Rajkumar RP; Kattimani S; Dkhar SA
Eur J Clin Pharmacol; 2013 Aug; 69(8):1497-509. PubMed ID: 23545936
[TBL] [Abstract][Full Text] [Related]
17. Lurasidone in schizophrenia: new information about dosage and place in therapy.
Citrome L
Adv Ther; 2012 Oct; 29(10):815-25. PubMed ID: 23001538
[TBL] [Abstract][Full Text] [Related]
18. G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders.
Wong TS; Li G; Li S; Gao W; Chen G; Gan S; Zhang M; Li H; Wu S; Du Y
Signal Transduct Target Ther; 2023 May; 8(1):177. PubMed ID: 37137892
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
